X4 Pharmaceuticals (XFOR)Deep Track Capital, LP reduced its stake -461K shares

5.88M

Shares reported · -461K vs prior quarter

0.40%

Disclosed portfolio weight

$27.5M

Reported value

Holdings as of

Jun 30, 2026

Filed

Aug 14, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Jun 30, 2026Company filing · Form 8-K · Executive change, Reg FDChanged a top executive or board member, and shared information with investors“On June 30, 2026, of X4 Pharmaceuticals, Inc. (the “Company”) appointed Kelly Gold as a Class II director of the Company, effective as of July 1, 2026. In connection with Ms. Gold’s appointment, the size of the Company’s board of directors (the “Board”) was increased from five to six directors.”
2. Jun 30, 2026InsiderCFO sold ~$36K of XFOR shares in the open market
3. Aug 12, 2026Insider · 2 peopleInsiders: 2 sales (~$320K)

What came next

1. Oct 1, 2026InsiderCFO sold ~$34K of XFOR shares in the open market
2. Oct 7, 2026Company filing · Form 8-K · Material agreement, Agreement endedSigned an important agreement, and ended an important agreement (and 3 more items)
3. Oct 7, 20265% stakeFMR LLC reported a passive stake (13G) of 4.6%

How to read SEC Form 13F-HR

Form 13F is the quarterly report in which investment managers that oversee $100 million or more list the US-listed stocks and some other securities they held on the last day of the quarter.

Full guide: What is an SEC Form 13F?

What else is on file for X4 Pharmaceuticals

For X4 Pharmaceuticals, OQRO holds 3 insider filings (SEC Form 4 or Form 144) and 3 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its XFOR page.

How this filing works

• SEC Form 13F

Other disclosures at X4 Pharmaceuticals

• SEC Schedule 13GOct 7, 2026
• SEC Form 4Oct 6, 2026
• SEC Form 4Aug 14, 2026
• SEC Form 4Aug 14, 2026
• SEC Form 13F-HRAug 14, 2026
• SEC Form 4Jul 2, 2026

Everything OQRO holds on this company is on its XFOR page.